Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells .
